Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an announcement.
Shanghai Fosun Pharmaceutical announced the repurchase and cancellation of 897,140 restricted shares under its 2022 Restricted A Share Incentive Scheme, due to resignations and unmet performance indicators. This move will reduce the company’s total issued share capital and registered capital, reflecting a strategic adjustment in its incentive scheme to align with performance and participation changes.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company based in China, operating in the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products, medical devices, and healthcare services, serving both domestic and international markets.
YTD Price Performance: 10.51%
Average Trading Volume: 5,648
Technical Sentiment Signal: Hold
Current Market Cap: $7.77B
For an in-depth examination of 2196 stock, go to TipRanks’ Stock Analysis page.